FDA postpones first stop on Crawford listening tour

Share this article:
The FDA has postponed the first session in its Vision 2006 consumer listening tour to give FDA Commissioner Lester Crawford and other top FDA officials more time to concentrate on relief efforts in connection with Hurricane Katrina, an FDA spokeswoman told MM&M today. 
The first stop on the question and answer tour to hear consumer concerns was scheduled to take place in Miami on Tuesday, Sept. 13. Rescheduling details were not made available, as Hurricane relief efforts are a "priority" right now, the spokeswoman added.
The Vision 2006 sessions on Nov. 2 in Boston and a Nov. 30 in Phoenix were scheduled to proceed as planned, the agency said.
The 10 a.m. to 4 p.m. sessions will include at least 150 consumers, with time devoted to such issues as drug advertising, conflicts of interest among federal advisers and drug safety.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...